[Carcinoma of the anal canal: state of art, issues in geriatric oncology and molecular targeted therapies].

Date publication

février 2011

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MERROUCHE Yacine

Tous les auteurs :
Hau Desbat NH, Auberdiac P, Chargari C, Merrouche Y, Deutsch E, Schmitt T, de Laroche G, Magné N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21382795

Résumé

Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy.

Mots clés

Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Anus Neoplasms, pathology, Carcinoma, Squamous Cell, pathology, Combined Modality Therapy, methods, Female, Humans, Male, Molecular Targeted Therapy, Neoplasm Staging, methods, Practice Guidelines as Topic, Radiotherapy, methods

Référence

Bull Cancer. 2011 Feb;98(2):146-53